SCHEMBL4259825

SCHEMBL4259825

C1=CCC(c2ccccc2)OC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.54
CYP2C19 P33261 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
SLC6A2 P23975 2/20 0.36
SLC6A3 Q01959 2/20 0.36
SLC6A4 P31645 1/20 0.36
MAOB P27338 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
AR P10275 1/20 0.35
CYP19A1 P11511 1/20 0.35
HSD17B10 Q99714 1/20 0.35
ADRA2A P08913 3/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
ADRA1A P35348 3/20 0.34
HTR1A P08908 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15300808 0.79 SLC6A2 (0.40) TSHRCYP2C19SLC6A2SLC6A3SLC6A4
SCHEMBL8234528 0.75 DRD2 (0.44) TSHRMAOBCYP19A1MAOA
SCHEMBL6384626 0.75 CYP2C19 (0.58) TSHRCYP2C19MEN1KMT2ASLC6A2
SCHEMBL15349821 0.74 CHRNB4 (0.40) TSHR
SCHEMBL5156811 0.71 TSHR (0.50) TSHRCYP2C19MEN1KMT2ASLC6A2
SCHEMBL1176630 0.71 TSHR (0.50) TSHRCYP2C19MEN1KMT2ASLC6A2
SCHEMBL987488 0.71
SCHEMBL1943997 0.71
SCHEMBL21026 0.71
SCHEMBL28467238 0.71 TSHR (1.00) TSHRCYP2C19MEN1KMT2ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4214303-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2023-07-26 EP claimed
WO-2022058048-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS GIVAUDAN SA (CH) 2022-03-24 WO claimed
US-12486471-B2 Perfume formulation for delivery system FIRMENICH SA (CH) 2025-12-02 US disclosed
US-12480075-B2 Perfume delivery system FIRMENICH SA (CH) 2025-11-25 US disclosed
US-12377407-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-08-05 US disclosed
US-20250042854-A1 IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF ECOLE NAT SUPERIEURE DE CHIMIE DE RENNES (FR) 2025-02-06 US disclosed
EP-4433451-A1 IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF Ecole Nationale Supérieure de Chimie de Rennes (FR) 2024-09-25 EP disclosed
EP-4214303-A1 IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS Givaudan SA (CH) 2023-07-26 EP disclosed
WO-2023088919-A1 IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF ECOLE NATIONALE SUPÉRIEURE DE CHIMIE DE RENNES (FR) 2023-05-25 WO disclosed
US-20230040744-A1 Perfume Formulation for Delivery System FIRMENICH SA (CH) 2023-02-09 US disclosed
US-20230036889-A1 Perfume Delivery System FIRMENICH SA (CH) 2023-02-02 US disclosed
WO-2013010676-A2 SUPPORTED IONIC LIQUID PHASE CATALYST ECOLE NATIONALE SUPERIEURE DE CHIMIE DE RENNES (FR) 2013-01-24 WO disclosed
WO-2011117571-A1 RUTHENIUM COMPLEXES FOR USE IN OLEFIN METATHESIS UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2011-09-29 WO disclosed
US-20110009621-A1 SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS Raap Polymere GmbH (DE) 2011-01-13 US disclosed
US-20110009621-A1 SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS Raap Polymere GmbH (DE) 2011-01-13 US disclosed
US-20090170692-A1 CATALYSTS FOR RING-CLOSING METATHESIS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH 2009-07-02 US disclosed
WO-2009009597-A1 WATER SOLUBLE OLEFIN METATHESIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-01-15 WO disclosed
WO-2009009597-A1 WATER SOLUBLE OLEFIN METATHESIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-01-15 WO disclosed
WO-2007117221-A1 CATALYSTS FOR RING CLOSING METATHESIS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2007-10-18 WO disclosed
WO-2007065907-A1 SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS RAPP POLYMERE GMBH (DE) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110009621-A1 SUPPORTED TRANSITION METAL COMPLEX AND USE THEREOF IN CATALYSIS SCO2, SOD1, PPIF TSHR 4727/4885CYP2C19 938/4885MEN1 266/4885
US-12377407-B2 Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis PPOX, CYBA, CYBB TSHR 4806/4885CYP2C19 883/4885MEN1 1935/4885
US-20250042854-A1 IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF SQLE, SYMPK, FDFT1 TSHR 4508/4885CYP2C19 1923/4885MEN1 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.